LAVA Therapeutics/$LVTX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About LAVA Therapeutics
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.
Ticker
$LVTX
Sector
Primary listing
Employees
34
Headquarters
Website
LVTX Metrics
BasicAdvanced
$42M
-
-$0.87
-
-
Price and volume
Market cap
$42M
52-week high
$1.69
52-week low
$1.03
Average daily volume
388K
Financial strength
Current ratio
12.268
Quick ratio
11.738
Interest coverage (TTM)
-66.25%
Profitability
EBITDA (TTM)
-25.303
Gross margin (TTM)
-391.98%
Net profit margin (TTM)
-465.25%
Operating margin (TTM)
-511.18%
Effective tax rate (TTM)
-3.03%
Revenue per employee (TTM)
$150,000
Management effectiveness
Return on assets (TTM)
-23.57%
Return on equity (TTM)
-101.65%
Valuation
Price to revenue (TTM)
8.676
Price to book
3.41
Price to tangible book (TTM)
3.41
Price to free cash flow (TTM)
-1.348
Free cash flow yield (TTM)
-74.19%
Free cash flow per share (TTM)
-1.194
Growth
Revenue change (TTM)
-32.06%
Earnings per share change (TTM)
-14.91%
3-year revenue growth (CAGR)
-34.57%
3-year earnings per share growth (CAGR)
-3.95%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for LAVA Therapeutics stock?
LAVA Therapeutics (LVTX) has a market cap of $42M as of November 08, 2025.
What is the P/E ratio for LAVA Therapeutics stock?
The price to earnings (P/E) ratio for LAVA Therapeutics (LVTX) stock is 0 as of November 08, 2025.
Does LAVA Therapeutics stock pay dividends?
No, LAVA Therapeutics (LVTX) stock does not pay dividends to its shareholders as of November 08, 2025.
When is the next LAVA Therapeutics dividend payment date?
LAVA Therapeutics (LVTX) stock does not pay dividends to its shareholders.
What is the beta indicator for LAVA Therapeutics?
LAVA Therapeutics (LVTX) does not currently have a Beta indicator.